Therefore, our results supported that TRPM2 represented a potential therapeutic target for ameliorating NLRP3 inflammasome activation related to hyperglycemia-induced oxidative stress in T2DM. The gene discussed is NLRP3; the disease is type 2 diabetes mellitus.